Topic: Obesity Medicine

PBS aired a segment promoting the use of weight-loss drugs like Wegovy for children as young as 12, citing a 600% increase in usage. The hosts criticize the report as "native advertising," arguing that the medical establishment is using chemicals to treat symptoms of a toxic food supply rather than addressing dietary causes.

A study from the London School of Hygiene and Tropical Medicine is highlighted, which links obesity to global warming by claiming heavier people consume more resources and drive more. The hosts discuss the potential for this narrative to lead to government intervention, citing instances in the UK where children were removed from homes due to obesity.

Dr. Jen Ashton reported on preliminary data suggesting that the weight loss drug Wegovy may reduce the risk of heart attacks and strokes by 20%. The drug maker plans to seek FDA approval for cardiovascular indications, which could expand insurance coverage. The segment also examines the credentials of the American Board of Obesity Medicine and the societal stigma surrounding medical weight loss interventions.

The hosts critique several "medical news" segments from ABC and NBC as thinly veiled native advertisements for Novo Nordisk and Pfizer. They point out that a pill version of semaglutide, Rybelsus, is already on the market for diabetes, but the current media blitz is focused on rebranding it specifically for weight loss. A Stanford doctor's claim that the drug is "safe and effective" is met with skepticism given the known side effects.